This is a working overview of bremelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-15 and is reviewed periodically as new material appears.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
| Property | Value | Notes |
|---|---|---|
| Storage form | Lyophilized powder | Longer stability at -20 °C |
| Reconstitution solvent | Sterile water or buffer | Depends on intended application |
| Purity assessment | Reverse-phase HPLC | Reported as peak area percentage |
| Identity confirmation | Mass spectrometry | Compared against theoretical mass |
| Main stability concern | Repeated freeze-thaw | May promote aggregation |
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
== Description == The cap of this mushroom grows up to 8–30 cm (3–12 in) wide, sometimes more. Viscid when moist, the cap is convex when young and flattens with age. The colour is generally reddish-brown, sometimes with a paler margin. The stipe grows up to 8–25 cm (3–10 in) tall and 2–7 cm (1–3 in) thick—rather large in comparison to the cap. The stem is usually enlarged at the base when young, becoming more cylindrical in age. It is finely reticulate on the upper portion or sometimes the whole. The flesh of the stem is sometimes dark yellow near the base. The undersurface of the cap consists of thin tubes, the site of spore production; they are 1 to 2 cm (1⁄2 to 3⁄4 in) deep, and whitish in colour when young, but mature to a greenish-yellow. The angular pores, which do not stain when bruised, are small—roughly 2 to 3 pores per millimetre. In youth, the pores are white and appear as if stuffed with cotton (which are actually mycelia); as they age, they change colour to yellow and later to brown. The spore print is olive brown. The flesh of the fruit body is white, thick and firm when young, but becomes somewhat spongy with age. When bruised or cut, it either does not change colour, or turns a very light brown or light red. Mature specimens can weigh about 1 kg (2 lb 3 oz). A huge specimen collected on the Isle of Skye, Scotland, in 1995 weighed 3.2 kg (7 lb 1 oz); its cap was 42 cm (16+1⁄2 in) wide and the stipe was 18 cm (7 in) tall and 14 cm (5+1⁄2 in) wide. A similarly sized specimen found in Poland in 2013 made international news.
MRI requires a magnetic field that is both strong and uniform to a few parts per million across the scan volume. The field strength of the magnet is measured in teslas – and while the majority of systems operate at 1.5 T, commercial systems are available between 0.2 and 7 T. 3T MRI systems, also called 3 Tesla MRIs, have stronger magnets than 1.5 systems and are considered better for images of organs and soft tissue. Whole-body MRI systems for research applications operate in e.g. 9.4T, 10.5T, 11.7T. Even higher field whole-body MRI systems e.g. 14 T and beyond are in conceptual proposal or in engineering design. Most clinical magnets are superconducting magnets, which require liquid helium to keep them at low temperatures. Lower field strengths can be achieved with permanent magnets, which are often used in "open" MRI scanners for claustrophobic patients. Lower field strengths are also used in a portable MRI scanner approved by the FDA in 2020. Recently, MRI has been demonstrated also at ultra-low fields, i.e., in the microtesla-to-millitesla range, where sufficient signal quality is made possible by prepolarization (on the order of 10–100 mT) and by measuring the Larmor precession fields at about 100 microtesla with highly sensitive superconducting quantum interference devices (SQUIDs).
Low neutrophil counts are termed neutropenia. This can be congenital (developed at or before birth) or it can develop later, as in the case of aplastic anemia or some kinds of leukemia. It can also be a side-effect of medication, most prominently chemotherapy. Neutropenia makes an individual highly susceptible to infections. It can also be the result of colonization by intracellular neutrophilic parasites. In alpha 1-antitrypsin deficiency, the important neutrophil elastase is not adequately inhibited by alpha 1-antitrypsin, leading to excessive tissue damage in the presence of inflammation – the most prominent one being emphysema. Negative effects of elastase have also been shown in cases when the neutrophils are excessively activated (in otherwise healthy individuals) and release the enzyme in extracellular space. Unregulated activity of neutrophil elastase can lead to disruption of pulmonary barrier showing symptoms corresponding with acute lung injury. The enzyme also influences activity of macrophages by cleaving their toll-like receptors (TLRs) and downregulating cytokine expression by inhibiting nuclear translocation of NF-κB. In Familial Mediterranean fever (FMF), a mutation in the pyrin (or marenostrin) gene, which is expressed mainly in neutrophil granulocytes, leads to a constitutively active acute-phase response and causes attacks of fever, arthralgia, peritonitis, and – eventually – amyloidosis. Hyperglycemia can lead to neutrophil dysfunction.
Xavier Bichat introduced the word tissue into the study of anatomy by 1801. He was "the first to propose that tissue is a central element in human anatomy, and he considered organs as collections of often disparate tissues, rather than as entities in themselves". Although he worked without a microscope, Bichat distinguished 21 types of elementary tissues from which the organs of the human body are composed, a number later reduced by other authors. In 2013, the work of de Bono et al introduced the concept of the Functional Tissue Unit (FTU) as a biophysical definition of spatial tissue domains that satisfy both long-range and short range (i.e., local) communication constraints for cellular maintenance and supracellular organization (i.e., architecture). A FTU consists of a cylindrical diffusive field of parenchyma centered around a tube. This central tube conveys long-range flow of a body fluid (e.g., blood, bile, air, urinary ultra-filtrate). It is compelling to draw parallels between the biophysical constraints that act upon a tissue domain and those acting on a protein domain. In this analogy, the FTU’s central tube is akin to the peptide backbone in a protein domain, and the cells in the surrounding diffusive cuff are analogous to interacting amino acid side chains.
Sources: en.wikipedia.org
== Effects and properties == The effects of argiotoxin, when it enters an organism by a spider bite, are harmless to humans, although in certain cases the bite of argiotoxin spiders can produce mild swelling and itching. Argiotoxin antagonizes the actions of the neurotransmitter glutamate, blocks the functioning of ion channel and affects the synaptic transmission of preys. These toxins, like all the other low-molecular-weight toxins, have a huge potential to be used in neurochemical studies to develop novel drugs of neurotherapeutic applications.
== Food sources == Xanthophylls are found in all young leaves and in etiolated leaves. Examples of other rich sources include papaya, peaches, prunes, and squash, which contain lutein diesters. Kale contains about 18 mg lutein and zeaxanthin per 100g, spinach about 11 mg/100g, parsley about 6 mg/100g, peas about 3 mg/110g, squash about 2 mg/100g, and pistachios about 1 mg/100g.
== Environmental risk factors == Exposures to pesticides, metals, solvents (trichloroethylene), other toxicants (carbon disulfide), and air pollution are known factors in the development of Parkinson's disease. The World Health Organization (WHO) recommends reducing exposure to environmental factors associated with PD, including pesticides, trichloroethylene (TCE), and air pollution. Pesticides, TCE and some air pollutants appear to trigger PD pathology through their effects on key mechanisms involved in mitochondrial dysfunction, oxidative stress, and neuroinflammation. The cumulative effects of many different environmental exposures over a lifetime (the exposome) interact with underlying genetic factors to influence the development and progression of neurodegenerative diseases. The brain is particularly vulnerable to compounds that are able to cross the blood-brain barrier. Body-first and brain-first models of Parkinson's disease indicate possible connections between known environmental risk factors and PD mechanisms. Toxicants such as pesticides, industrial chemicals, and air pollution are usually inhaled, ingested, or both. In the nasal cavity and gut, they engage directly with mucosal surfaces where inflammation can occur. Pathways which can carry inflammation and toxins from the olfactory system and gut to the brain are well established. Key mechanisms are increasingly understood.
Sources: en.wikipedia.org
Gestation in bats ranges from around 40 days to eight months, correlating with the size of the species. In most bat species, females carry and give birth to a single pup per litter. A newborn bat pup can be up to 40 percent of the mother's weight, and the pelvic girdle of the female can expand during birth as the two halves are connected by a flexible ligament. Females typically give birth upright or horizontally, using gravity to make the process easier. The young emerges rear-first, possibly to prevent the wings from becoming tangled, and the female holds it in her wing and tail membranes. In many species, females give birth and raise their young in maternity colonies and may assist each other in birthing. Most of the care for a young bat comes from the mother, though in monogamous species, the father plays a role. Allo-suckling, where a female suckles another mother's young, occurs in several species. This may serve to increase colony size in species where females breed in their birth colonies. Young bats can fly after they develop their adult body dimensions and forelimb length. For the little brown bat, this occurs when they are eighteen days old. Weaning of young for most species takes place in under 80 days. The common vampire bat nurses its offspring beyond that, and young vampire bats achieve independence later in life than other species. This is probably due to the species's blood-based diet, as the female may not be able to feed on a nightly basis.
Collagen XXIII belongs to the transmembranous subfamily of collagens. Proteins which are included in this group present an amino-terminal cytoplasmic domain followed by a membrane-spanning hydrophobic domain and at least one extracellular triple-helical collagenous domain alternated with short non-collagenous domains. Collagens XIII, XVII, and XXV, and related proteins such as class A macrophage scavenger receptors, ectodysplasin A or the MARCO1 receptor, are also part of this group. An alternative name for this type of protein is MACITs (membrane-associated collagens with interrupted triple helices). Collagen XXIII shows structural homology with collagen XIII and collagen XXV . Apart from having the characteristic structure of transmembranous collagens, all three proteins present a high level of amino acid residue conservation in collagenous and non-collagenous domains. Collagens α1(XIII), α1(XXIII) and α1(XXV) display three collagenous domains (Col 1, Col 2, and Col 3) and four non-collagenous domains (NC1, which is also a transmembranous domain, NC2, NC3 and NC4). It has been reported that Col 1 domain of α1(XXIII) shows similarities with regions of both Col 1 and Col 2 domains of collagen types α1(XIII) and α1(XXV), whilst sequences of Col 2 and Col 3 domains of α1(XXIII) are related to the Col 3 domain of types α1(XIII)and α1(XXV). Short non-collagenous domains also exhibit similarities, especially in the NC1 and NC4 domains. Between 60 and 78% of the amino acid residues of these domains are identical in all three chains.
Fluorine-18 (18F, also called radiofluorine) is a fluorine radioisotope which is an important source of positrons. Its half-life is 109.734 minutes, less than two hours, and one of the shortest of radioisotopes with use outside research. It decays by positron emission 96.7% of the time and electron capture 3.3% of the time. Both modes of decay yield stable oxygen-18.
Sources: en.wikipedia.org
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.
Reverse-phase HPLC separates components by hydrophobicity and reports purity as a percentage of total peak area. It does not by itself confirm molecular identity. Mass spectrometry is used alongside it for that purpose.
They link a specific lot to its analytical results and storage history. This traceability supports reproducibility when results differ between experiments. Records also help identify when re-testing is warranted.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.